In a newly diagnosed type 2 diabetes patient with HbA1c 9.2%, what is first-line pharmacotherapy after lifestyle modifications?

Study for the Medical Council of Canada Qualifying Examination (MCCQE) I. Engage with flashcards and multiple-choice questions with detailed feedback. Prepare confidently!

Multiple Choice

In a newly diagnosed type 2 diabetes patient with HbA1c 9.2%, what is first-line pharmacotherapy after lifestyle modifications?

Starting therapy with metformin after lifestyle changes is the best first step for a newly diagnosed type 2 diabetes patient with an HbA1c of 9.2%. Metformin works by reducing hepatic glucose production and improving insulin sensitivity, leading to a meaningful drop in blood sugar without causing hypoglycemia when used alone. It also tends to be weight-neutral or even support slight weight loss, is inexpensive, and has a long track record of safety. Because of this favorable balance of effectiveness, safety, and cost, it’s the preferred initial medication. Begin at a low dose and gradually increase to improve tolerance, since metformin commonly causes gastrointestinal side effects. Regularly monitor kidney function, and be mindful of contraindications such as significant renal impairment or risk of lactic acidosis. Schedule follow-up in a few months to assess response; if glycemic targets aren’t reached, add or switch to another agent based on patient needs and comorbidities. Other options—insulin, sulfonylureas, or GLP-1 receptor agonists—are not first-line in this scenario. Insulin is typically reserved for marked hyperglycemia or symptomatic presentation; sulfonylureas carry hypoglycemia and weight gain risks; GLP-1 receptor agonists are injectable, more costly, and usually considered after metformin or in specific clinical contexts.

Starting therapy with metformin after lifestyle changes is the best first step for a newly diagnosed type 2 diabetes patient with an HbA1c of 9.2%. Metformin works by reducing hepatic glucose production and improving insulin sensitivity, leading to a meaningful drop in blood sugar without causing hypoglycemia when used alone. It also tends to be weight-neutral or even support slight weight loss, is inexpensive, and has a long track record of safety. Because of this favorable balance of effectiveness, safety, and cost, it’s the preferred initial medication.

Begin at a low dose and gradually increase to improve tolerance, since metformin commonly causes gastrointestinal side effects. Regularly monitor kidney function, and be mindful of contraindications such as significant renal impairment or risk of lactic acidosis. Schedule follow-up in a few months to assess response; if glycemic targets aren’t reached, add or switch to another agent based on patient needs and comorbidities.

Other options—insulin, sulfonylureas, or GLP-1 receptor agonists—are not first-line in this scenario. Insulin is typically reserved for marked hyperglycemia or symptomatic presentation; sulfonylureas carry hypoglycemia and weight gain risks; GLP-1 receptor agonists are injectable, more costly, and usually considered after metformin or in specific clinical contexts.

More practice questions